20(top 2%)
papers
1.3K(top 2%)
citations
13(top 2%)
h-index
21(top 2%)
g-index
22
all documents
1.4K
doc citations
452
citing journals

Top Articles

#TitleJournalYearCitations
1ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisMultiple Sclerosis Journal2018458
2ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosisEuropean Journal of Neurology2018147
3Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJournal of Neurology, Neurosurgery and Psychiatry2016137
4Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM StudyJAMA Neurology2021132
5Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseAnnals of Neurology2021123
6Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paperMultiple Sclerosis Journal2016118
7Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility StudyJournal of Medical Internet Research201990
8Sex effects across the lifespan in women with multiple sclerosisTherapeutic Advances in Neurological Disorders202058
9Targeting Inflammasomes to Treat Neurological DiseasesAnnals of Neurology202146
10Natalizumab: Risk Stratification of Individual Patients with Multiple SclerosisCNS Drugs201424
11Risk Acceptance in Multiple Sclerosis Patients on Natalizumab TreatmentPLoS ONE201323
12HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosisJournal of Medical Genetics201419
13Matrix metalloproteinase 9 is decreased in natalizumab‐treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathyAnnals of Neurology201714
14Classic Block Design “Pseudo”‐Resting‐State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple SclerosisJournal of Neuroimaging201814
15Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysisJournal of Neurology, Neurosurgery and Psychiatry20239
16Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II GeneAmerican Journal of Pathology20148
17Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of EuropeJournal of the Neurological Sciences20158
18CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: NoMultiple Sclerosis Journal20136
19A new cognitive rehabilitation programme for patients with multiple sclerosis: the ‘MS-line! Project’Multiple Sclerosis Journal20153
20Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapyHematological Oncology20222
21Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosisMultiple Sclerosis Journal20130